New schizophrenia drug could treat Alzheimer’s disease. The drug is KarXT, sold as Cobenfy. It targets muscarinic receptors and leads to antipsychotic and cognitive benefits. Xanomeline, one of the active components of the drug, acts mostly on two of the five muscarinic receptors: the M1 and M4